ÂÜÀòÂÒÂ×

Emmanuelle Astoul has over 20 years of experience in the field of biotechnology. Emmanuelle began their career in 1997 as a Marie Curie Postdoctoral Fellow at Cancer Research UK (CRUK). In 2001, they moved to The Babraham Institute as a Post Doctoral Fellow, eventually becoming a Career Progression Fellow. In 2005, they joined Babraham Bioscience Technologies Ltd as a Knowledge Transfer Manager. From 2010 to 2011, they were a Business Analyst at the Wellcome Trust. In 2011, they became a Board Observer at Senexis Limited. In 2015, they joined Congenica as a Board Observer. From 2012 to 2020, they worked at the Wellcome Sanger Institute, first as a Senior Business Development Manager and then as an Associate Head of Business Development. In 2020, they became the Head of Licensing at Transine Therapeutics. In 2022, they will become the Head of Translation at the Wellcome Sanger Institute.

Emmanuelle Astoul obtained their Doctor of Philosophy in Immunology and Toxicology from Pierre and Marie Curie University in 1996.